Skyrizi
Skyrizi
Skyrizi (risankizumab) is a monoclonal antibody used to treat moderate-to-severe plaque psoriasis in adults. It works by targeting and inhibiting interleukin-23 (IL-23), a protein that drives inflammation, helping to reduce skin lesions and improve symptoms.
Delivery
5-7 day
In Stock
Yes
Guaranteed
Source Canadian/UK PharmaciesWhat It Is & How It Works
Skyrizi is an IL-23 antagonist—a monoclonal antibody designed to block IL-23A, a critical driver of inflammation in autoimmune diseases.
Approved Uses
-
Plaque Psoriasis: For adults with moderate to severe disease requiring systemic therapy or phototherapy
-
Psoriatic Arthritis: Treats active inflammation in adult patients.
-
Crohn’s Disease and Ulcerative Colitis: Approved for moderately to severely active disease in adults
Administration & Dosing
-
Available in a 150 mg/mL prefilled pen or syringe for subcutaneous injection.
Dosing schedule: Two initial doses spaced 4 weeks apart, followed by a maintenance dose every 12 weeks.
-
For Crohn’s disease and ulcerative colitis, initial treatment may require an intravenous infusion followed by subcutaneous injections for maintenance.
Injection Features (Skyrizi Pen)
The pen is designed with safety and ease-of-use in mind:
-
Comes locked to prevent accidental activation.
-
Features a large window for viewing medication.
-
Equipped with a button that clicks at injection start and end.
-
Has a rubber-lined grip for better handling.
Safety & Considerations
-
Hypersensitivity reactions, including rare anaphylaxis, can occur.
-
Increased risk of infections; screening for existing infections—including TB—is recommended before starting treatment.
-
For diseases impacting the liver (e.g. Crohn’s or ulcerative colitis), checking liver enzymes prior to treatment is advised.